Every 8-K that Cbdmd Inc (YCBD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow YCBD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full YCBD filings page.
cbdMD, Inc. (YCBD) entered into an Asset Purchase Agreement to acquire operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and Alvita Tea, through an assignment for the benefit of creditors, subject to ABC Court approval and customary closing conditions. Consideration includes assumption of approximately $1,750,000 of secured debt, issuance of 2,229,805 common shares (equal to 19.9% of outstanding shares on signing, with a target of 19.99% at closing), and assumption of specified liabilities; the stock issued to the secured creditor will be subject to leak-out restrictions.
The agreement provides for reimbursement of cbdMD’s expenses up to $300,000 and a breakup fee equal to 4% of the purchase price under certain termination scenarios. Based on unaudited data, combined trailing-twelve-month revenue to June 2026 is about $30 million, roughly 40% above cbdMD’s standalone revenue. Separately, cbdMD amended its Series B Convertible Preferred Stock designation, reducing the common stock conversion price from $1.00 to $0.60 per share for the 591,207 Series B shares outstanding, increasing potential dilution.
cbdMD, Inc. has extended and restructured the lease for its combined warehouse and executive offices at 2101 Westinghouse Boulevard in Charlotte, North Carolina.
The Third Amendment to Lease extends the term for 62 months beginning on October 1, 2026, creating a new expiration date of November 30, 2031 for 40,000 square feet of space. The amendment reduces monthly base rent to $38,000 for the initial year of the renewal term, with annual base rent of $9.75 per square foot from March 1, 2025 through February 28, 2026, increasing up to $13.87 per square foot for the final two months of the term. Monthly base rent is fully abated from October 1, 2026 through November 30, 2026.
Management states that reducing the leased footprint to 40,000 square feet is sufficient for current and expected operations and that remaining in the current facility aligns with the company’s long-term needs. The company estimates an annual reduction in gross rent expense of approximately $450,000 and a net rent expense reduction of about $100,000 to $120,000 per year after accounting for ongoing sublet income.
cbdMD, Inc. updated its director compensation program. On April 14, 2026, the board granted each independent director and the non-management employee director 1,572 restricted stock units (RSUs) under the 2025 Equity Compensation Plan for the term beginning March 31, 2026. These RSUs vest in four equal quarterly installments on June 30, 2026, September 30, 2026, December 31, 2026 and March 31, 2027, with value based on the common stock closing price on April 14, 2026. The board also set annual cash fees, including a $35,000 retainer per independent director and additional amounts for the board chair and key committee roles.
cbdMD, Inc. reported that shareholders approved its 2025 Equity Compensation Plan, creating a new stock-based incentive program for employees, directors and consultants. The plan initially reserves 891,316 shares of common stock for options, restricted stock and other equity awards.
The plan includes an evergreen formula that can increase the share pool each year by 2% of shares outstanding on September 30, up to 300,000 shares annually. With shareholder approval, a previously contingent 445,000-share restricted stock award to CEO and CFO T. Ronan Kennedy became effective. At the 2026 annual meeting, 10,495,561 shares were entitled to vote and a quorum of 54.6% was reached, with all seven proposals approved.
cbdMD, Inc. entered into an Asset Purchase Agreement to acquire substantially all assets of Gaia Botanicals, LLC, including the Bluebird Botanicals brand, its online CBD marketplace at https://www.bluebirdbotanicals.com/, related trademarks, inventory, and certain other assets, while assuming specified liabilities. This expands cbdMD’s portfolio into additional CBD products such as gummies, oils, soft gels, creams, and pet products.
The purchase price consists of 425,000 shares of cbdMD restricted common stock issued at closing and an earnout of up to 525,000 additional restricted shares, based on earnout share calculations and setoff rights in the agreement. Earnout shares, if earned, will be issued on or before the 60th day following the first anniversary of closing. All closing and earnout shares are subject to a 180‑day lockup with limited transfer and dribble‑out provisions. The share issuance was an unregistered private offering relying on Section 4(a)(2) of the Securities Act.
cbdMD, Inc. reported that it has regained full compliance with the continued listing standards of the NYSE American exchange. NYSE Regulation sent the company a letter on December 5, 2025 confirming that previously identified deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide have been resolved. As a result, the “.BC” below-compliance indicator will be removed from cbdMD’s ticker and the company will be taken off the exchange’s list of noncompliant issuers, while remaining subject to normal ongoing listing monitoring.
cbdMD, Inc. reported a new executive employment agreement and a fresh equity compensation plan. The company entered into a three-year agreement with CEO and CFO T. Ronan Kennedy, providing a base salary of $340,000 and a restricted stock award covering 445,000 shares of common stock under the new 2025 Equity Compensation Plan. Vesting and issuance of these shares are subject to shareholder approval.
The board approved the 2025 Equity Compensation Plan, which reserves 891,316 shares of common stock for options, restricted stock, and other stock-based awards. The plan includes an “evergreen” feature that can automatically increase the share pool annually based on a percentage of shares outstanding, subject to caps. Awards may be granted to employees, officers, directors, and consultants and are administered by the board’s Compensation, Corporate Governance and Nominating Committee. Grants under the plan will not vest until shareholders approve it, and incentive stock option treatment depends on that approval.
cbdMD, Inc. filed a Form 8-K to report that on November 21, 2025 it issued a press release announcing preliminary net revenues for its fourth quarter and fiscal year ended September 30, 2025, along with certain other operating data for those periods. The press release is included as Exhibit 99.1.
The company states that this information is being furnished, not filed, under the securities laws, which means it is not subject to certain liability provisions and is not automatically incorporated into other cbdMD, Inc. filings.
cbdMD, Inc. issued 1,700,000 shares of newly designated Series B Convertible Preferred Stock to four institutional investors for aggregate gross proceeds of $1,700,000 and net proceeds of $1,500,000, to be used for working capital. Each preferred share converts into common stock at a conversion price of $1.00 subject to anti-dilution and special conversion rights. The Series B accrues dividends at 10% per annum payable quarterly in common shares or cash subject to defined equity conditions; unpaid dividends may increase the stated value if cash payment is restricted by North Carolina law. The preferred ranks senior on liquidation, carries no voting rights except as required by law, and includes a 4.99% beneficial ownership cap on conversion. The company agreed to file a registration statement for the underlying common shares within 30 days of closing per registration rights agreements.